Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leisl Packer

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Cancer Cell|April 13, 2011
Unswitch-ABL drugs overcome resistance in chronic myeloid leukemiaLeisl Packer, Richard Marais
Cancer Treatment and Research Communications|April 29, 2025
Durvalumab consolidation after chemoradiotherapy in unresectable stage III non-small cell lung cancer: A real-world experience from the Australian subset of PACIFIC-RBen Markman, Steven Kao, Nick Pavlakis, et al.
Melanoma Research|July 18, 2006
Increased p21-activated kinase-1 expression is associated with invasive potential in uveal melanomaSandra Pavey, Wieke Zuidervaart, Frans van Nieuwpoort, et al.
Cancer Cell|January 11, 2011
Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5AImanol Arozarena, Berta Sanchez-Laorden, Leisl Packer, et al.
Carcinogenesis|March 31, 2006
Osteopontin is a downstream effector of the PI3-kinase pathway in melanomas that is inversely correlated with functional PTENLeisl Packer, Sandra Pavey, Andrew Parker, et al.
Melanoma Research|November 10, 2007
Expression of Wnt5a and its downstream effector beta-catenin in uveal melanomaWieke Zuidervaart, Sandra Pavey, Frans A van Nieuwpoort, et al.
Oncogene|March 30, 2004
Microarray expression profiling in melanoma reveals a BRAF mutation signatureSandra Pavey, Peter Johansson, Leisl Packer, et al.
Cancer Research|March 11, 2010
Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244)Jonathan R Dry, Sandra Pavey, Christine A Pratilas, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Cancer Cell|April 13, 2011
Unswitch-ABL drugs overcome resistance in chronic myeloid leukemiaLeisl Packer, Richard Marais
Cancer Treatment and Research Communications|April 29, 2025
Durvalumab consolidation after chemoradiotherapy in unresectable stage III non-small cell lung cancer: A real-world experience from the Australian subset of PACIFIC-RBen Markman, Steven Kao, Nick Pavlakis, et al.
Melanoma Research|July 18, 2006
Increased p21-activated kinase-1 expression is associated with invasive potential in uveal melanomaSandra Pavey, Wieke Zuidervaart, Frans van Nieuwpoort, et al.
Cancer Cell|January 11, 2011
Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5AImanol Arozarena, Berta Sanchez-Laorden, Leisl Packer, et al.
Carcinogenesis|March 31, 2006
Osteopontin is a downstream effector of the PI3-kinase pathway in melanomas that is inversely correlated with functional PTENLeisl Packer, Sandra Pavey, Andrew Parker, et al.
Melanoma Research|November 10, 2007
Expression of Wnt5a and its downstream effector beta-catenin in uveal melanomaWieke Zuidervaart, Sandra Pavey, Frans A van Nieuwpoort, et al.
Oncogene|March 30, 2004
Microarray expression profiling in melanoma reveals a BRAF mutation signatureSandra Pavey, Peter Johansson, Leisl Packer, et al.
Cancer Research|March 11, 2010
Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244)Jonathan R Dry, Sandra Pavey, Christine A Pratilas, et al.
Pageof 1